Our study shows that men who have the AR-V7 gene variant and usually don't respond to either abiraterone or enzalutamide, are not at a drawback when given chemotherapy drugs, says Emmanuel Antonarakis, M.D., an oncologist at the Kimmel Cancer Center. Seven of the 17 men in the trial who carried the AR-V7 variant and received chemotherapy experienced a 50 % reduction in their prostate-specific antigen level. The National Malignancy Institute estimates that a lot more than 220,000 men will be diagnosed with prostate cancer in 2015 and more than 27,000 will die from it.Most People in america say they don’t really believe Medicare needs to be cut to stability the federal budget, and ditto for Sociable Security, a fresh poll displays. The Associated Press-GfK poll suggests that arguments for overhauling the substantial benefit applications to pare government personal debt have didn’t sway the general public. The debate is definitely unlikely to become resolved before following year’s elections for president and Congress . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an independent news service editorially, is a scheduled program of the Kaiser Family Foundation, a nonpartisan health care policy research business unaffiliated with Kaiser Permanente..